Matthew Pauls, the CHIEF EXECUTIVE OFFICER of $SVRA ($SVRA), sold 54,702 shares of the company on 12-16-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.4%...
Joseph S McCracken, a director at $SVRA ($SVRA), bought 20,000 shares of the company on 11-19-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...
September S&P 500 E-Mini futures (ESU24) are up +0.74%, and September Nasdaq 100 E-Mini futures (NQU24) are up +0.95% this morning, partially rebounding from Friday’s losses driven by weaker-than-expected...
The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2022 and...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointments of two pharmaceutical industry veterans to its executive leadership...